S
Seongwoo Hwang
Publications - 3
Citations - 1407
Seongwoo Hwang is an academic researcher. The author has contributed to research in topics: Ataluren & Nonsense mutation. The author has an hindex of 3, co-authored 3 publications receiving 1293 citations.
Papers
More filters
Journal ArticleDOI
PTC124 targets genetic disorders caused by nonsense mutations
Ellen Welch,Elisabeth R. Barton,Jin Zhuo,Yuki Tomizawa,Westley J. Friesen,Panayiota Trifillis,Sergey Paushkin,Meenal Patel,Christopher R. Trotta,Seongwoo Hwang,Wilde Richard Gerald,Gary Mitchell Karp,James J. Takasugi,Guangming Chen,S. M. Jones,Hongyu Ren,Young-Choon Moon,Donald Thomas Corson,Anthony Turpoff,Jeffrey Allen Campbell,M. Morgan Conn,Atiyya Khan,Neil G. Almstead,Jean Hedrick,Anna Mollin,Nicole Risher,Marla Weetall,Shirley Yeh,Arthur Branstrom,Joseph M. Colacino,John Babiak,William D. Ju,Samit Hirawat,Valerie Northcutt,Langdon L. Miller,Phyllis Spatrick,Feng He,Masataka Kawana,Huisheng Feng,Allan Jacobson,Stuart W. Peltz,H. Lee Sweeney +41 more
TL;DR: The selectivity of PTC124 for premature termination codons, its well characterized activity profile, oral bioavailability and pharmacological properties indicate that this drug may have broad clinical potential for the treatment of a large group of genetic disorders with limited or no therapeutic options.
Journal ArticleDOI
Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single‐ and Multiple‐Dose Administration to Healthy Male and Female Adult Volunteers
Samit Hirawat,Ellen Welch,Gary Elfring,Valerie Northcutt,Sergey Paushkin,Seongwoo Hwang,Eileen M. Leonard,Neil Gregory Almstead,William D. Ju,Stuart W. Peltz,Langdon L. Miller +10 more
TL;DR: Data support initiation of phase II studies of PTC124 in patients with nonsense mutation–mediated cystic fibrosis and Duchenne muscular dystrophy.
Journal ArticleDOI
Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties
Liangxian Cao,Marla Weetall,Christopher R. Trotta,Katherine Cintron,Jiyuan Ma,Min Jung Kim,Bansri Furia,Charles M. Romfo,Jason D. Graci,Wencheng Li,Joshua Du,Josephine Sheedy,Jean Hedrick,Nicole Risher,Shirley Yeh,Hongyan Qi,Tamil Arasu,Seongwoo Hwang,William Joseph Lennox,Ronald Kong,Janet Petruska,Young-Choon Moon,John Babiak,Thomas W. Davis,Allan Jacobson,Neil Gregory Almstead,Art Branstrom,Joseph M. Colacino,Stuart W. Peltz +28 more
TL;DR: PTC299 has advantages over previously reported DHODH inhibitors, including greater potency, good oral bioavailability, and lack of off-target kinase inhibition and myelosuppression, and thus may be useful for the targeted treatment of hematologic malignancies.